THERAPY DOSSIER · th-5bfd0c20f44b

MALAT1 long noncoding RNA knockdown

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29631367 ↗2018Reported benefit

Long noncoding RNA MALAT1 contributes to inflammatory response of microglia following spinal cord injury via the modulation of a miR-199b/IKKbeta/NF-kappaB signaling pathway.

RatSpinal cord injuryContusionSprague-Dawley (per MeSH indexing)

Model: Acute contusion spinal cord injury in adult rats

MALAT1 was raised 2.4-fold at the contusion epicentre with IKKbeta/NF-kappaB activation and higher TNF-alpha and IL-1beta. MALAT1 knockdown improved hindlimb locomotor recovery and lowered TNF-alpha, IL-1beta and Iba-1 in injured cords.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…